In latest trials, the NeuroAD cranial device from Israel’s Neuronix (see here) slowed the progression of the disease in 85% of patients suffering mild Alzheimer’s.  The treatment is now being used commercially in the UK (London, Berkshire, Chester and Manchester).

http://www.prnewswire.co.uk/news-releases/neuronix-reports-positive-results-from-its-multi-center-alzheimers-study-at-the-clinical-trials-in-alzheimers-disease-ctad-conference-609622515.html